NurExone Biologic (STU:J90) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:J90 NurExone Biologic Inc STU:J90
28 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic FFO?

FFO (Funds from operations) only applies to REITs.

STU:J90
28GF Score
NurExone Biologic Inc STU:J90
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Business Description

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
28GF Score

Get the complete analysis for STU:J90

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price